Sensus Healthcare Q2 revenue down 68.5% to $2.3M; net loss $8.7M

Sensus Healthcare, Inc.

Revenue $2.3M vs $7.3M in Q2 2025; 11 units sold vs 19, with 8 units deferred to Q3 on financing timing.
Net loss $8.7M ($0.53/share) vs $1.0M ($0.06/share); includes $5.7M valuation allowance on deferred tax assets.
Adjusted EBITDA negative $3.0M vs negative $1.8M; gross margin 34.8% vs 39.7% on product mix.
CMS proposed 26% increase in hospital-based SRT delivery code, if finalized would improve provider economics.
Management cites strong pipeline, expanded Asia-Pacific activity (Australia, New Zealand); expects strong H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.